Market Research Logo

Oncology/Cancer Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical

Oncology/Cancer Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

Oncology Drugs Market Overview:

The global oncology/cancer drugs market was valued at $97,401 million in 2017, and is estimated to reach at $176,509 million by 2025, registering a CAGR of 7.6% from 2018 to 2025.

Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option to treat various cancer types, especially blood cancer (leukemia). Rise in incidence of various cancer conditions, increase in popularity of advance therapies (biological and targeted drug therapies), and surge in geriatric population worldwide are the key factors driving the growth of the global oncology/cancer drugs market. Furthermore, rise in cancer awareness and availability of cancer drugs are expected to boost the market growth.

However, high cost involved in new drug development coupled with threat of failure & adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and increase in number of pipeline products are expected to provide new opportunities for market players in future.

The global oncology/cancer drugs market is segmented based on drug class type, indication, and region. Depending on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers.

Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Key Benefits for Oncology Drugs Market:

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
Oncology Drugs Key Market Segments:

By Drug Class Type

Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy

By Indication

Lung Cancer
Stomach Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Esophagus Cancer
Cervical Cancer
Kidney Cancer
Bladder Cancer
Other Cancers

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
India
China
Japan
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA

List of Key Players Profiled in the Report

AbbVie Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Bristol-Myers Squibb Company
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Johnson & Johnson (Janssen Global Services, LLC,)
Merck & Co., Inc.
Novartis AG
Pfizer Inc.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

Sanofi
Amgen Inc.
Bayer AG
Exelixis, Inc.


CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2017
3.3. Top player positioning, 2017
3.4. Porters five forces analysis
3.5. Clinical trials
3.6. Patent analysis (2015-2018)
3.6.1. Patent analysis, world
3.6.2. Patent analysis, by year
3.7. Market dynamics
3.7.1. Drivers
3.7.1.1. Rise in incidence of cancer across the globe
3.7.1.2. Surge in global geriatric population
3.7.1.3. Increase in government expenditures on healthcare
3.7.2. Restraints
3.7.2.1. Adverse effects associated with the use of cancer drugs
3.7.3. Opportunities
3.7.3.1. Untapped emerging economies
3.7.3.2. Increase in number of pipeline drugs
3.7.4. Impact Analyses
CHAPTER 4: ONCOLOGY/ CANCER DRUGS MARKET, BY DRUG CLASS TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Chemotherapy
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Targeted Therapy
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Immunotherapy (Biologic Therapy)
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Hormonal Therapy
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
CHAPTER 5: ONCOLOGY/ CANCER DRUGS MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Lung Cancer
5.2.1. Market size and forecast, by region
5.2.2. Market share analysis, by country
5.3. Stomach Cancer
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Colorectal Cancer
5.4.1. Market size and forecast, by region
5.4.2. Market share analysis, by country
5.5. Breast Cancer
5.5.1. Market size and forecast, by region
5.5.2. Market share analysis, by country
5.6. Prostate Cancer
5.6.1. Market size and forecast, by region
5.6.2. Market share analysis, by country
5.7. Liver Cancer
5.7.1. Market size and forecast, by region
5.7.2. Market share analysis, by country
5.8. Esophagus Cancer
5.8.1. Market size and forecast, by region
5.8.2. Market share analysis, by country
5.9. Cervical Cancer
5.9.1. Market size and forecast, by region
5.9.2. Market share analysis, by country
5.10. Kidney Cancer
5.10.1. Market size and forecast, by region
5.10.2. Market share analysis, by country
5.11. Bladder Cancer
5.11.1. Market size and forecast, by region
5.11.2. Market share analysis, by country
5.12. Other Cancers
5.12.1. Market size and forecast, by region
5.12.2. Market share analysis, by country
CHAPTER 6: ONCOLOGY/ CANCER DRUGS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. oncology/cancer drugs market, by drug class type
6.2.2.1.2. U.S. oncology/cancer drugs market, by indication
6.2.2.2. Canada
6.2.2.2.1. Canada oncology/cancer drugs market, by drug class type
6.2.2.2.2. Canada oncology/cancer drugs market, by indication
6.2.2.3. Mexico
6.2.2.3.1. Mexico oncology/cancer drugs market, by drug class type
6.2.2.3.2. Mexico oncology/cancer drugs market, by indication
6.2.3. Market size and forecast, by drug class type
6.2.4. Market size and forecast, by indication
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Germany oncology/cancer drugs market, by drug class type
6.3.2.1.2. Germany oncology/cancer drugs market, by indication
6.3.2.2. France
6.3.2.2.1. France oncology/cancer drugs market, by drug class type
6.3.2.2.2. France oncology/cancer drugs market, by indication
6.3.2.3. UK
6.3.2.3.1. UK oncology/cancer drugs market, by drug class type
6.3.2.3.2. UK oncology/cancer drugs market, by indication
6.3.2.4. Italy
6.3.2.4.1. Italy oncology/cancer drugs market, by drug class type
6.3.2.4.2. Italy oncology/cancer drugs market, by indication
6.3.2.5. Spain
6.3.2.5.1. Spain oncology/cancer drugs market, by drug class type
6.3.2.5.2. Spain oncology/cancer drugs market, by indication
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe oncology/cancer drugs market, by drug class type
6.3.2.6.2. Rest of Europe oncology/cancer drugs market, by indication
6.3.3. Market size and forecast, by drug class type
6.3.4. Market size and forecast, by indication
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan oncology/cancer drugs market, by drug class type
6.4.2.1.2. Japan oncology/cancer drugs market, by indication
6.4.2.2. China
6.4.2.2.1. China oncology/cancer drugs market, by drug class type
6.4.2.2.2. China oncology/cancer drugs market, by indication
6.4.2.3. Australia
6.4.2.3.1. Australia oncology/cancer drugs market, by drug class type
6.4.2.3.2. Australia oncology/cancer drugs market, by indication
6.4.2.4. India
6.4.2.4.1. India oncology/cancer drugs market, by drug class type
6.4.2.4.2. India oncology/cancer drugs market, by indication
6.4.2.5. South Korea
6.4.2.5.1. South Korea oncology/cancer drugs market, by drug class type
6.4.2.5.2. South Korea oncology/cancer drugs market, by indication
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Rest of Asia-Pacific oncology/cancer drugs market, by drug class type
6.4.2.6.2. Rest of Asia-Pacific oncology/cancer drugs market, by indication
6.4.3. Market size and forecast, by drug class type
6.4.4. Market size and forecast, by indication
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil oncology/cancer drugs market, by drug class type
6.5.2.1.2. Brazil oncology/cancer drugs market, by indication
6.5.2.2. Saudi Arabia
6.5.2.2.1. Saudi Arabia oncology/cancer drugs market, by drug class type
6.5.2.2.2. Saudi Arabia oncology/cancer drugs market, by indication
6.5.2.3. South Africa
6.5.2.3.1. South Africa oncology/cancer drugs market, by drug class type
6.5.2.3.2. South Africa oncology/cancer drugs market, by indication
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA oncology/cancer drugs market, by drug class type
6.5.2.4.2. Rest of LAMEA oncology/cancer drugs market, by indication
6.5.3. Market size and forecast, by drug class type
6.5.4. Market size and forecast, by indication
CHAPTER 7: COMPANY PROFILES
7.1. AbbVie Inc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. Astellas Pharma Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product Portfolio
7.2.5. Business performance
7.3. AstraZeneca PLC
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product Portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments
7.4. Bristol-Myers Squibb Company
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product Portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. Celgene Corporation
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product type Portfolio
7.5.5. Business performance
7.6. F. HOFFMANN-LA ROCHE LTD.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. JOHNSON & JOHNSON (Janssen Global Services, LLC,)
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product Portfolio
7.7.5. Business performance
7.8. Merck & Co., Inc.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product Portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Novartis AG
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance
7.10. Pfizer Inc.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance
LIST OF TABLES
TABLE 01. PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 02. LESS THAN 1 CU. FT. PORTABLE MINI FRIDGE MARKET, BY REGION, 20172025 ($MILLION)
TABLE 03. 1 1.9 CU. FT. PORTABLE MINI FRIDGE MARKET, BY REGION, 20172025 ($MILLION)
TABLE 04. 2 2.9 CU. FT. PORTABLE MINI FRIDGE MARKET, BY REGION, 20172025 ($MILLION)
TABLE 05. 3 3.9 CU. FT. PORTABLE MINI FRIDGE MARKET, BY REGION, 20172025 ($MILLION)
TABLE 06. 4 5 CU. FT. PORTABLE MINI FRIDGE MARKET, BY REGION, 20172025 ($MILLION)
TABLE 07. PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 08. PORTABLE MINI FRIDGE FOR COMMERCIAL USE, BY REGION, 20172025 ($MILLION)
TABLE 09. PORTABLE MINI FRIDGE FOR HOME USE, BY REGION, 20172025 ($MILLION)
TABLE 10. PORTABLE MINI FRIDGE MARKET, BY REGION, 20172025 ($MILLION)
TABLE 11. NORTH AMERICA PORTABLE MINI FRIDGE MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 12. NORTH AMERICA PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 13. NORTH AMERICA PORTABLE MINI FRIDGE MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 14. U.S. PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 15. U.S. PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 16. CANADA PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 17. CANADA PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 18. MEXICO PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 19. MEXICO PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 20. EUROPE POWDER MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 21. EUROPE POWDER MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 22. EUROPE PORTABLE MINI FRIDGE MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 23. GERMANY PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 24. GERMANY PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 25. UK PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 26. UK PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 27. FRANCE PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 28. FRANCE PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 29. RUSSIA PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 30. RUSSIA PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 31. BENELUX PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 32. BENELUX PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 33. ITALY PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 34. ITALY PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 35. SPAIN PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 36. SPAIN PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 37. REST OF EUROPE PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 38. REST OF EUROPE PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 39. ASIA-PACIFIC PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 40. ASIA-PACIFIC PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 41. ASIA-PACIFIC PORTABLE MINI FRIDGE MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 42. CHINA PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 43. CHINA PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 44. JAPAN PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 45. JAPAN PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 46. INDIA PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 47. INDIA PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 48. AUSTRALIA PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 49. AUSTRALIA PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 50. SOUTH KOREA PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 51. SOUTH KOREA PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 52. REST OF ASIA-PACIFIC PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 53. REST OF ASIA-PACIFIC PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 54. LAMEA PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 55. LAMEA PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 56. LAMEA PORTABLE MINI FRIDGE MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 57. BRAZIL PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 58. BRAZIL PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 59. SAUDI ARABIA PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 60. SAUDI ARABIA PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 61. SOUTH AFRICA PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 62. SOUTH AFRICA PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 63. REST OF LAMEA PORTABLE MINI FRIDGE MARKET, BY TYPE, 20172025 ($MILLION)
TABLE 64. REST OF LAMEA PORTABLE MINI FRIDGE MARKET, BY APPLICATION, 20172025 ($MILLION)
TABLE 65. ARB: COMPANY SNAPSHOT
TABLE 66. ARB: OPERATING SEGMENTS
TABLE 67. ARB: PRODUCT PORTFOLIO
TABLE 68. ARB: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 69. DANBY: COMPANY SNAPSHOT
TABLE 70. DANBY: PRODUCT PORTFOLIO
TABLE 71. DANBY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 72. DOMETIC GROUP AB: COMPANY SNAPSHOT
TABLE 73. DOMETIC GROUP AB: OPERATING SEGMENTS
TABLE 74. DOMETIC GROUP AB: PRODUCT PORTFOLIO
TABLE 75. DOMETIC GROUP AB: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 76. EDGESTAR (LIVING DIRECT, INC.): COMPANY SNAPSHOT
TABLE 77. EDGESTAR (LIVING DIRECT, INC.): OPERATING SEGMENTS
TABLE 78. EDGESTAR (LIVING DIRECT, INC.): PRODUCT PORTFOLIO
TABLE 79. HAIER INC.: COMPANY SNAPSHOT
TABLE 80. HAIER INC.: OPERATING SEGMENTS
TABLE 81. HAIER INC.: PRODUCT PORTFOLIO
TABLE 82. HAIER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 83. KOOLATRON CA: COMPANY SNAPSHOT
TABLE 84. KOOLATRON CA: PRODUCT PORTFOLIO
TABLE 85. LG ELECTRONIC: COMPANY SNAPSHOT
TABLE 86. LG ELECTRONIC: OPERATING SEGMENTS
TABLE 87. LG ELECTRONIC: PRODUCT PORTFOLIO
TABLE 88. GODREJ INDUSTRIES: COMPANY SNAPSHOT
TABLE 89. GODREJ INDUSTRIES: OPERATING SEGMENTS
TABLE 90. GODREJ INDUSTRIES: PRODUCT PORTFOLIO
TABLE 91. GODREJ INDUSTRIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 92. ENGEL AUSTRALIA PTY LTD.: COMPANY SNAPSHOT
TABLE 93. ENGEL AUSTRALIA PTY LTD.: PRODUCT PORTFOLIO
TABLE 94. WHYNTER LLC: COMPANY SNAPSHOT
TABLE 95. WHYNTER LLC: OPERATING SEGMENTS
TABLE 96. WHYNTER LLC: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. ONCOLOGY/CANCER DRUGS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, 2015-2018
FIGURE 04. TOP WINNING STRATEGIES, BY YEAR, 2015-2018
FIGURE 05. TOP WINNING STRATEGIES: NATURE AND TYPE, 2015-2018
FIGURE 06. TOP PLAYER POSITIONING, 2017
FIGURE 07. MODERATE BARGANING POWER OF BUYERS
FIGURE 08. HIGH BARGANING POWER OF SUPPLIERS
FIGURE 09. MODERATE THREAT OF SUBSTITUTION
FIGURE 10. MODERATE THREAT OF NEW ENTRANTS
FIGURE 11. HIGH COMPETITIVE RIVALRY
FIGURE 12. PATENTS REGISTERED/APPROVED IN THE WORLD, 2015-2018
FIGURE 13. PATENTS ANALYSIS BY YEAR, 2015 THROUGH 2018
FIGURE 14. WORLD POPULATION AGED 65 AND OVER (%)
FIGURE 15. IMPACT ANALYSES, ONCOLOGY/CANCER DRUGS MARKET
FIGURE 16. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2017 & 2025
FIGURE 17. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR TARGETED THERAPY, BY COUNTRY, 2017 & 2025
FIGURE 18. COMPARATIVE ANALYSIS OF CANCER DRUGS FOR IMMUNOTHERAPY, BY COUNTRY, 2017 & 2025
FIGURE 19. COMPARATIVE ANALYSIS OF CANCER DRUGS FOR HORMONAL THERAPY, BY COUNTRY, 2017 & 2025
FIGURE 20. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR LUNG CANCER, BY COUNTRY, 2017 & 2025
FIGURE 21. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR STOMACH CANCER, BY COUNTRY, 2017 & 2025
FIGURE 22. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2017 & 2025
FIGURE 23. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR BREAST CANCER, BY COUNTRY, 2017 & 2025
FIGURE 24. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2017 & 2025
FIGURE 25. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR LIVER CANCER, BY COUNTRY, 2017 & 2025
FIGURE 26. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR ESOPHAGUS CANCER, BY COUNTRY, 2017 & 2025
FIGURE 27. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR CERVICAL CANCER, BY COUNTRY, 2017 & 2025
FIGURE 28. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR KIDNEY CANCER, BY COUNTRY, 2017 & 2025
FIGURE 29. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR BLADDER CANCER, BY COUNTRY, 2017 & 2025
FIGURE 30. COMPARATIVE ANALYSIS OF ONCOLOGY/CANCER DRUGS MARKET FOR OTHER CANCERS, BY COUNTRY, 2017 & 2025
FIGURE 31. EUROPEAN GERIATRIC POPULATION (ABOVE 65 YEARS), 2017
FIGURE 32. ABBVIE: NET SALES, 20152017 ($MILLION)
FIGURE 33. ABBVIE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 34. ABBVIE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 35. ASTELLAS: SALES, 20152017 ($MILLION)
FIGURE 36. ASTELLAS: SALES SHARE BY PRODUCTS AND SERVICES, 2017 (%)
FIGURE 37. ASTELLAS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 38. ASTRAZENECA: REVENUE, 20152017 ($MILLION)
FIGURE 39. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 40. REVENUE, 20152017 ($MILLION)
FIGURE 41. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 42. CELGENE: REVENUE, 20152017 ($MILLION)
FIGURE 43. CELGENE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 44. CELGENE: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 45. ROCHE: NET SALES, 20152017 ($MILLION)
FIGURE 46. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 47. ROCHE: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 48. J&J: REVENUE, 20152017 ($MILLION)
FIGURE 49. J&J: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 50. J&J: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 51. MERCK: NET SALES, 20152017 ($MILLION)
FIGURE 52. MERCK: NET SALES BY SEGMENT, 2017 (%)
FIGURE 53. MERCK: NET SALES BY GEOGRAPHY, 2017 (%)
FIGURE 54. NET SALES, 20152017 ($MILLION)
FIGURE 55. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 56. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 57. PFIZER: REVENUE, 20152017 ($MILLION)
FIGURE 58. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 59. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report